Screening for Prostate, Breast and Colorectal Cancer in Renal Transplant Recipients

  title={Screening for Prostate, Breast and Colorectal Cancer in Renal Transplant Recipients},
  author={Bryce A. Kiberd and Tammy M Keough-Ryan and Catherine M. Clase},
  journal={American Journal of Transplantation},
American Society of Transplantation guidelines recommend screening renal transplant recipients for breast, colorectal and prostate cancer. However there is a lack of evidence to support this practice. 

Prostate cancer characteristics and outcome in renal transplant recipients: results from a contemporary single center study

Prostate cancer (PCa) incidence is expected to increase in renal transplant recipients (RTR) with no clear nor contemporary data on management and oncological outcome.

Utility of mammography for chronic kidney disease patients undergoing kidney transplant evaluation

The effect of age and other breast malignancy risk factors on screening MMG in the pre‐transplant renal failure population undergoing transplant evaluation is sought.

Cumulative incidence of cancer after solid organ transplantation

Solid organ transplantation recipients have elevated cancer incidence. Estimates of absolute cancer risk after transplantation can inform prevention and screening.

Immediate renal transplantation after radical prostatectomy for low‐risk prostate cancer

Using available predictive models for prostate cancer recurrence, it is examined whether current evidence supports a prolonged waiting period after radical prostatectomy and before renal transplantation.

Cancer after Kidney Transplantation in the United States

A large number of patients in single‐center studies and incomplete ascertainment of cases in large registries suggest that cancer after kidney transplantation is a major cause of death in these patients.

The clinical perspective on malignancies in renal transplanted patients

This thesis investigated malignancies in renal transplanted patients from a clinical viewpoint and found that the use of regional tumours in patients with post-transplant malignancy is a viable treatment option.

Kidney Transplantation Long-Term Management Challenges De Novo Malignancies after Kidney Transplantation

countries. The excess risk of cancer after transplantation is approximately two to three times higher than the age- and sex-matched general population, driven largely by viral- and immune-related

Managing Cancer Risk and Decision Making After Kidney Transplantation

  • A. WebsterG. WongJ. CraigJ. Chapman
  • Medicine
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2008
Critically examine the assumptions underpinning primary prevention, immunization, chemoprevention and screening programs, and highlight considerations when applying evidence to the kidney transplant population, and suggest a clinical research agenda that aims to define a rational approach to managing posttransplant cancer risk.

Breast Cancer and Transplantation

  • G. WongE. AuS. BadveW. Lim
  • Medicine
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2017
The focus of this review is to present the epidemiology of breast cancer inSolid organ transplant recipients, screening and preventive strategies for those who may be at risk, novel genomic profiling for determining tumor progression, and the newer targeted interventions for recipients who have developed breast cancers after solid organ transplantation.



Reduced incidence of rectal cancer, compared to gastric and colonic cancer, in a population of 73,076 men and women chronically immunosuppressed.

It is concluded that an analysis of immune function in gut-associated lymphoid tissue in the stomach, colon, and rectum in healthy and immunosuppressed patients may lead to a better understanding of immunosurveillance in the colon and immune promotion of rectal cancers.

Cost-effectiveness of cancer screening in end-stage renal disease.

Routine cancer screening in the population with ESRD is a relatively inefficient allocation of financial resources, and direction of funds toward improving the quality of dialysis could attain such an objective at substantially lower cost.

Malignancies after renal transplantation: the EDTA-ERA registry experience. European Dialysis and Transplantation Association-European Renal Association.

  • F. BrunnerP. LandaisN. Selwood
  • Medicine, Biology
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 1995
Survival after diagnosis of cancer at the most frequent sites, such as bronchopulmonary, breast, oesophagogastric and colorectal cancer, did not differ between non-grafted patient groups on dialysis and those who developed the tumour while carrying a functioning renal transplant.

Screening for prostate cancer. A decision analytic view.

The analysis does not support using PSA, TRUS, or DRE to screen asymptomatic men for prostatic cancer, and Screening may result in poorer health outcomes and will increase costs dramatically.

CLINICAL GUIDELINES: PART II: Early Detection of Prostate Cancer: Part II

Evidence of treatment effectiveness and the effectiveness of screening tests are synthesized and the cost-effectiveness of one-time screening for prostate cancer with digital rectal examination and measurement of prostate-specific antigen (PSA) is estimated.

Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care.

The results show that total costs vary by stage at diagnosis and age, but the patterns of variation differ for each cancer.

Life expectancy benefits of cancer screening in the end-stage renal disease population.

Screening for Colorectal Cancer: Recommendation and Rationale

The USPSTF concluded that the benefits from screening substantially outweigh potential harms, but the quality of evidence, magnitude of benefit, and potential harms vary with each method, and there are insufficient data to determine which screening strategy is best in terms of the balance of benefits and potential harm or cost-effectiveness.